China-United States Research Collaborations in Antimicrobial Resistance.

Published

Journal Article

A strong synergy can result from China-US antimicrobial resistance (AMR) collaborations given similarities and differences between their respective healthcare systems and research infrastructures. The Antibacterial Resistance Leadership Group has employed a model of realistic growth, starting with a feasible, relatively low-resource observational study in a critical priority pathogen. This and other observational studies will provide vital scientific information required for the rational design of future interventional trials. In addition, it provides a mutual, low-risk opportunity for determining the strengths and opportunities of the research collaboration. Issues identified during the observational studies can be addressed prior to the initiation of high-resource interventional studies. Collaborative clinical AMR studies between China and the United States have tremendous potential to decrease AMR rates, improve responsible antibiotic use, and ultimately improve the lives of patients in both countries.

Full Text

Duke Authors

Cited Authors

  • van Duin, D; Gu, P; Dong, J; Pfaff, M; Arias, RM; Evans, B; Yu, Y; Li, L; Zhang, F; Liu, Z; Cao, B; Fowler, VG; Wang, M

Published Date

  • November 13, 2018

Published In

Volume / Issue

  • 67 / suppl_2

Start / End Page

  • S142 - S145

PubMed ID

  • 30423056

Pubmed Central ID

  • 30423056

Electronic International Standard Serial Number (EISSN)

  • 1537-6591

Digital Object Identifier (DOI)

  • 10.1093/cid/ciy694

Language

  • eng

Conference Location

  • United States